WithdrawnNCT00457678
Second Line Therapy to Treat Age-related Macular Degeneration (AMD) for Patients Not Responding Well to Lucentis Therapy by Itself
PHASE2 · 0 planned enrolment
- Countries listed
- 0
- Registry update
- August 23, 2017
immortal.lifeTrial registrations containing the exact intervention label Visudyne.
No aliases or equivalent products have been inferred.
This is a registry availability fact, not a safety result, comparison, or conclusion.
Understand the safety boundary →PHASE2 · 0 planned enrolment
PHASE3 · 304 planned enrolment
PHASE2 · 106 planned enrolment